Septic Shock clinical trials at UCSF

2 in progress, 1 open to eligible people

Septic shock occurs when an infection triggers extremely low blood pressure in the body. UCSF examines how hydrocortisone might aid children experiencing septic shock. The study evaluates both the advantages and potential drawbacks of this intervention.

Showing trials for

  • Stress Hydrocortisone In Pediatric Septic Shock

    open to eligible people ages 1 month to 17 years

    SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).

    Oakland, California and other locations

  • Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

    Sorry, in progress, not accepting new patients

    Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock

    San Francisco, California and other locations

Our lead scientists for Septic Shock research studies include .

Last updated: